202 related articles for article (PubMed ID: 15176000)
1. Increasing tumor uptake of anticancer drugs with imatinib.
Pietras K
Semin Oncol; 2004 Apr; 31(2 Suppl 6):18-23. PubMed ID: 15176000
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
3. Role of KIT and platelet-derived growth factor receptors as oncoproteins.
Fletcher JA
Semin Oncol; 2004 Apr; 31(2 Suppl 6):4-11. PubMed ID: 15175998
[TBL] [Abstract][Full Text] [Related]
4. A widening prospect: Imatinib and novel applications of targeted therapy.
Rowinsky EK
Semin Oncol; 2004 Apr; 31(2 Suppl 6):1-3. PubMed ID: 15175997
[No Abstract] [Full Text] [Related]
5. Pharmacology of imatinib (STI571).
Buchdunger E; O'Reilly T; Wood J
Eur J Cancer; 2002 Sep; 38 Suppl 5():S28-36. PubMed ID: 12528770
[TBL] [Abstract][Full Text] [Related]
6. PDGF receptors as targets in tumor treatment.
Ostman A; Heldin CH
Adv Cancer Res; 2007; 97():247-74. PubMed ID: 17419949
[TBL] [Abstract][Full Text] [Related]
7. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation.
Vlahovic G; Rabbani ZN; Herndon JE; Dewhirst MW; Vujaskovic Z
Br J Cancer; 2006 Oct; 95(8):1013-9. PubMed ID: 17003785
[TBL] [Abstract][Full Text] [Related]
8. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
Demetri GD
Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
[TBL] [Abstract][Full Text] [Related]
9. Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Deininger MW
J Cancer Res Clin Oncol; 2004 Feb; 130(2):59-72. PubMed ID: 14605878
[TBL] [Abstract][Full Text] [Related]
10. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors.
Pietras K; Ostman A; Sjöquist M; Buchdunger E; Reed RK; Heldin CH; Rubin K
Cancer Res; 2001 Apr; 61(7):2929-34. PubMed ID: 11306470
[TBL] [Abstract][Full Text] [Related]
12. Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia.
Knight GW; McLellan D
Br J Biomed Sci; 2004; 61(2):103-11. PubMed ID: 15250677
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
14. Cancer treatment. New drugs, new hope.
Harv Health Lett; 2001 Jul; 26(9):1-3. PubMed ID: 11511447
[No Abstract] [Full Text] [Related]
15. Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate.
George DJ
Urology; 2002 Sep; 60(3 Suppl 1):115-21; discussion 122. PubMed ID: 12231066
[TBL] [Abstract][Full Text] [Related]
16. KIT and PDGF as targets.
Verweij J
Cancer Treat Res; 2004; 120():117-27. PubMed ID: 15217221
[No Abstract] [Full Text] [Related]
17. Imatinib: a selective tyrosine kinase inhibitor.
Manley PW; Cowan-Jacob SW; Buchdunger E; Fabbro D; Fendrich G; Furet P; Meyer T; Zimmermann J
Eur J Cancer; 2002 Sep; 38 Suppl 5():S19-27. PubMed ID: 12528769
[TBL] [Abstract][Full Text] [Related]
18. Antagonism of platelet-derived growth factor receptor in non small cell lung cancer: rationale and investigations.
Bauman JE; Eaton KD; Martins RG
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4632-6. PubMed ID: 17671155
[TBL] [Abstract][Full Text] [Related]
19. From bedside to bench: treatment for rare blood disorder yields clues to disease mechanism.
Friedrich MJ
J Natl Cancer Inst; 2003 Aug; 95(15):1102-3. PubMed ID: 12902432
[No Abstract] [Full Text] [Related]
20. Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
George D
Semin Oncol; 2001 Oct; 28(5 Suppl 17):27-33. PubMed ID: 11740804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]